A Phase 1b Study to Assess the Anti-fatigability Effect of CK-2127107 in Elderly Male and Female Subjects With Limitations in Mobility
Phase of Trial: Phase I
Latest Information Update: 15 Feb 2018
At a glance
- Drugs Reldesemtiv (Primary)
- Indications Muscular atrophy
- Focus Therapeutic Use
- Sponsors Astellas Pharma
- 15 Feb 2018 According to a Cytokinetics media release, results are anticipated in 2H 2018.
- 15 Feb 2018 According to a Cytokinetics media release, this trial has enrolled over 20 subjects towards the objective of 60 subjects.
- 30 Nov 2017 According to a Cytokinetics media release, the results from this trial is anticipated in 2018.